CN113825758A - 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型 - Google Patents

抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型 Download PDF

Info

Publication number
CN113825758A
CN113825758A CN202080031672.2A CN202080031672A CN113825758A CN 113825758 A CN113825758 A CN 113825758A CN 202080031672 A CN202080031672 A CN 202080031672A CN 113825758 A CN113825758 A CN 113825758A
Authority
CN
China
Prior art keywords
degrees
compound
formula
angles
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080031672.2A
Other languages
English (en)
Other versions
CN113825758B (zh
Inventor
吴立方
孙飞
杜金华
丁照中
徐宏江
杨玲
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113825758A publication Critical patent/CN113825758A/zh
Application granted granted Critical
Publication of CN113825758B publication Critical patent/CN113825758B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请公开了一种新的抗HBV的四氢异噁唑并[4,3‑c]吡啶类化合物的晶型，具体公开了式(I)化合物的晶型、其水合物及其水合物的晶型，还包括所述晶型在制备抗HBV药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202080031672.2A 2019-05-14 2020-05-13 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型 Active CN113825758B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103992001 2019-05-14
CN201910399200 2019-05-14
PCT/CN2020/090059 WO2020228745A1 (zh) 2019-05-14 2020-05-13 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型

Publications (2)

Publication Number Publication Date
CN113825758A true CN113825758A (zh) 2021-12-21
CN113825758B CN113825758B (zh) 2023-08-01

Family

ID=73289379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031672.2A Active CN113825758B (zh) 2019-05-14 2020-05-13 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型

Country Status (2)

Country Link
CN (1) CN113825758B (zh)
WO (1) WO2020228745A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
CN102617536A (zh) * 2011-01-27 2012-08-01 上海瑞广生化科技开发有限公司 异黄酮类化合物,其制备方法及其在制备抗病毒或抗肿瘤药物中的应用
CN106061978A (zh) * 2014-03-07 2016-10-26 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6‑稠合的杂芳基二氢嘧啶
CN107207515A (zh) * 2015-01-16 2017-09-26 豪夫迈·罗氏有限公司 用于治疗感染性疾病的吡嗪化合物
CN107531691A (zh) * 2014-12-30 2018-01-02 诺维拉治疗公司 治疗乙型肝炎感染的衍生物和方法
WO2019096241A1 (zh) * 2017-11-16 2019-05-23 正大天晴药业集团股份有限公司 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物
WO2019126622A1 (en) * 2017-12-21 2019-06-27 Janssen Sciences Ireland Unlimited Company Isoxazole compounds for the treatment of diseases associated with hbv infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
CN102617536A (zh) * 2011-01-27 2012-08-01 上海瑞广生化科技开发有限公司 异黄酮类化合物,其制备方法及其在制备抗病毒或抗肿瘤药物中的应用
CN106061978A (zh) * 2014-03-07 2016-10-26 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6‑稠合的杂芳基二氢嘧啶
CN107531691A (zh) * 2014-12-30 2018-01-02 诺维拉治疗公司 治疗乙型肝炎感染的衍生物和方法
CN107207515A (zh) * 2015-01-16 2017-09-26 豪夫迈·罗氏有限公司 用于治疗感染性疾病的吡嗪化合物
WO2019096241A1 (zh) * 2017-11-16 2019-05-23 正大天晴药业集团股份有限公司 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物
WO2019126622A1 (en) * 2017-12-21 2019-06-27 Janssen Sciences Ireland Unlimited Company Isoxazole compounds for the treatment of diseases associated with hbv infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOORTHY S. S. PALANKI ET AL.: "Novel Inhibitors of AP-1 and NF- B Mediated Gene Expression:Structure±Activity Relationship Studies of Ethyl 4-[(3-Methyl-2,5-Dioxo(3-pyrrolinyl))amino]-2-(tri¯uoromethyl)pyrimidine-5-carboxylate", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
WO2020228745A1 (zh) 2020-11-19
CN113825758B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
CN105121437B (zh) 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
TW200846347A (en) Polymorphic forms of a macrocyclic inhibitor of HCV
CN114149476B (zh) 一种核糖核苷类似物的多晶型物、其制备方法及应用
CN113698405A (zh) 一种核苷类化合物的晶型及其制备方法
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
WO2012080195A2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
JP2023027319A (ja) 化合物の結晶形及び医学におけるその使用
EP4036078A1 (en) Crystalline form of capsid protein assembly inhibitor containing n hetero five-membered ring, and application thereof
WO2023078416A1 (zh) 一种异丁酸酯核苷化合物的晶型及制备方法
EP3712139A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
WO2021098850A1 (zh) 一种核蛋白抑制剂的晶型及其应用
EP2874628B1 (en) Salts and hydrates of antipsychotics
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US11192882B2 (en) Crystal form of small molecule immune compound, preparation method thereof and pharmaceutical composition containing the same
WO2020228745A1 (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
KR102397741B1 (ko) 세고리식 화합물의 결정 형태 및 이의 용도
CN111356676B (zh) 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法
CN115427397A (zh) 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用
CN113015722B (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
WO2023131017A1 (zh) 一种稠环衍生物的晶型、其制备方法及其应用
CN107337702B (zh) 结晶型hcv抑制剂及其制备方法和应用
WO2024078302A1 (zh) 一种酮酰胺衍生物的晶型以及其制备方法
WO2024078294A1 (zh) 酮酰胺衍生物的无定型及其制备方法
WO2022247885A9 (zh) 三并杂环类化合物的结晶和盐及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant